艾地苯醌联合依达拉奉治疗急性脑梗死临床研究

Clinical Study on Idebenone Combined with Edaravone in the Treatment of Acute Cerebral Infarction

目的探讨艾地苯醌联合依达拉奉治疗急性脑梗死的临床疗效,以及对血清氧化型低密度脂蛋白(oxLDL)水平的影响。方法选择医院2016年10月至2018年10月收治的急性脑梗死患者94例,随机分为对照组和研究组,各47例。两组患者均给予依达拉奉治疗,研究组患者联用艾地苯醌。结果研究组有效率为89.36%,显著高于对照组的70.21%(P<0.05);两组患者美国国立卫生研究院卒中量表(NIHSS)评分显著降低,日常生活能力量表(ADL)和简易精神状态量表(MMSE)评分均显著升高,且研究组显著优于对照组(P<0.05);治疗后,两组患者失语严重程度和各项言语功能评分均较治疗前显著改善,且研究组显著优于对照组(P<0.05);治疗后,两组患者oxLDL和氧化型低密度脂蛋白抗体(oxLDL-Ab)水平均显著降低,且研究组显著低于对照组(P<0.05);两组不良反应发生率相近(P>0.05)。结论艾地苯醌联合依达拉奉治疗急性脑梗死疗效显著,能明显改善患者的神经功能、日常生活能力、痴呆程度和运动性失语状况,初步机制分析可能与其降低血清oxLDL和oxLDL-Ab水平有关,且安全性较高。

Objective To investigate the clinical efficacy of idebenone combined with edaravone in the treatment of acute cerebral infarction and its effect on the level of serum oxidized low-density lipoprotein(oxLDL).Methods Totally 94 patients with acute cerebral infarction admitted to our hospital from October 2016 to October 2018 were selected and randomly divided into the control group and the study group,47 cases in each group.The patients in the two groups were treated with edaravone,on this basis,the patients in the study group were treated with idebenone.Results The effective rate of the study group was 89.36%,which was significantly higher than 70.21% of the control group(P<0.05).The score of National Institutes of Health Stroke Scale(NIHSS) in the two groups was significantly decreased(P<0.05),while the scores of Activity of Daily Living Scale(ADL) and Mini-Mental State Scale(MMSE) in the two groups were significantly increased(P<0.05),and those in the study group were significantly better than those in the control group(P<0.05).After treatment,the severity of aphasia and the score of speech function in the two groups were significantly improved,and those in the study group were significantly better than those in the control group(P<0.05).After treatment,the levels of serum oxLDL and oxLDL-Ab in the two groups were significantly decreased,and those in the study group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions was similar in the two groups(P>0.05).Conclusion Idebenone combined with edaravone is effective in the treatment of patients with acute cerebral infarction,which can significantly improve the neurological function,ADL,the degree of dementia and motor aphasia.The preliminary mechanism may be related to the reduction of serum oxLDL and oxLDL-Ab,and the safety of the drug is high.